US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

MetaVia Inc

0.7390

+0.00470.64%

Post-market: 0.74000.0010+0.14%19:59 EDT

Volume:598.93K

Turnover:420.88K

Market Cap:6.40M

PE:-0.21

High:0.7479

Open:0.7000

Low:0.6470

Close:0.7343

Loading ...

Overview Company News Filings

MetaVia Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

MTVA: Positive Phase 1 MAD Data for DA-1726; Excellent Tolerability Profile and Mean Day 26 Weight Loss of 4.3%…

Zacks Small Cap Research

BUZZ-U.S. STOCKS ON THE MOVE-Dow, Nike, Coty

Metavia Shares up 6.5% After Its Experimental Obesity Drug Shows Promise in Early-Stage Study

THOMSON REUTERS

BUZZ-MetaVia rises after experimental obesity drug shows promise in early-stage study

MetaVia announces ‘positive’ results from Part 2 of Phase 1 trial of DA-1726

Metavia Inc: Additional Cohorts Being Added to Determine Maximum Tolerated Dose

THOMSON REUTERS

Metavia: With No Titration, Demonstrated Maximum Weight Loss of 6.3% and Mean Weight Loss of 4.3% at Day 26 at 32 Mg Dose

THOMSON REUTERS

Metavia Announces Positive Top-Line Data From the 4-Week Phase 1 Mad Trial of Da-1726, a Novel 3:1 Ratio Glp-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-in-Class Glucose Control (Glp-1R), Waist Reduction (Gcgr), and Tolerability

THOMSON REUTERS

Metavia Inc: Study Shows Strong Signal of Glucagon Efficacy at Day 33 at 32 Mg Dos

THOMSON REUTERS

Metavia: Phase 1 Part 3 to Include Wegovy Early Drop-Out Patients to Explore Potential Superiority of Da-1726 on Safety and Tolerability

THOMSON REUTERS

MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and Tolerability

U.S. RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Beacon Roofing, Liberty Energy

MetaVia Inc. Reports Progress in Cardiometabolic Drug Development

MetaVia Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

MetaVia 2024 EPS $(3.56) Down From $(2.46) YoY

Press Release: MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update

Zacks Small Cap Research 2024 Initiations and Best Ideas for 2025

Zacks Small Cap Research

MetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 Conference

HC Wainwright Initiates MetaVia at Buy With $12 Price Target

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/MTVA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MTVA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MTVA\",,,,,undefined,":{"symbol":"MTVA","market":"US","secType":"STK","nameCN":"MetaVia Inc","latestPrice":0.739,"timestamp":1744920000000,"preClose":0.7343,"halted":0,"volume":598934,"hourTrading":{"tag":"盘后","latestPrice":0.74,"preClose":0.739,"latestTime":"19:59 EDT","volume":74920,"amount":56411.927041,"timestamp":1744934392880},"delay":0,"floatShares":2336574,"shares":8654869,"eps":-3.56,"marketStatus":"Closed Good Friday","change":0.0047,"latestTime":"04-17 16:00:00 EDT","open":0.7,"high":0.7479,"low":0.647,"amount":420875.6833253,"amplitude":0.13741,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-3.56,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"listingDate":1470369600000,"exchange":"NASDAQ","adjPreClose":0.7343,"preHourTrading":{"tag":"盘前","latestPrice":0.7155,"preClose":0.7323,"latestTime":"09:29 EDT","volume":15573,"amount":11280.1343616,"timestamp":1744896580399},"postHourTrading":{"tag":"盘后","latestPrice":0.74,"preClose":0.739,"latestTime":"19:59 EDT","volume":74920,"amount":56411.927041,"timestamp":1744934392880},"volumeRatio":0.11595326897331375},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MTVA\",,,,,undefined,":{"symbol":"MTVA","floatShares":2336574,"roa":"-92.24%","roe":"-224.18%","lyrEps":-3.556986,"volumeRatio":0.11595326897331375,"shares":8654869,"dividePrice":0,"high":0.7479,"amplitude":0.13741,"preClose":0.7343,"low":0.647,"week52Low":0.647,"pbRate":"0.81","week52High":5.3,"institutionHeld":0,"latestPrice":0.739,"eps":-3.56,"divideRate":0,"volume":598934,"delay":0,"ttmEps":-3.56,"open":0.7,"prevYearClose":2.03,"prevWeekClose":1.45,"prevMonthClose":1.54,"prevQuarterClose":1.54,"fiveDayClose":1.37,"twentyDayClose":1.55,"sixtyDayClose":1.88},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MTVA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2527021363","title":"MetaVia Price Target Maintained With a $12.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2527021363","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527021363?lang=en_us&edition=fundamental","pubTime":"2025-04-16 19:58","pubTimestamp":1744804680,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MTVA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 16, 2025 07:58 ET (11:58 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA"],"gpt_icon":0},{"id":"2527253442","title":"MTVA: Positive Phase 1 MAD Data for DA-1726; Excellent Tolerability Profile and Mean Day 26 Weight Loss of 4.3%…","url":"https://stock-news.laohu8.com/highlight/detail?id=2527253442","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527253442?lang=en_us&edition=fundamental","pubTime":"2025-04-16 18:27","pubTimestamp":1744799220,"startTime":"0","endTime":"0","summary":"On April 15, 2025, MetaVia Inc.  announced positive results from the Phase 1 Part 2 multiple ascending dose  trial of DA-1726 in obesity. The results showed that the cohort receiving 32 mg of DA-1726 with no titration had a maximum reduction in body weight from baseline ranging up to -6.3% and a mean body weight reduction of -4.3% . In addition, patients in the 32 mg cohort had a mean waist circumference reduction of 1.6 inches along with a mean reduction in fasting glucose of -5.3 mg/dL. Importantly, gastrointestinal  adverse events  were generally mild and most were only seen after the first dose and resolved within 24 hours of occurrence.The following chart shows the average weight loss on Day 26 for the different dosing cohorts. The 4 mg cohort had an outlier that skewed the overall average weight loss, however the 8 mg, 16 mg, and 32 mg cohorts show a clear dose response.Due to the strong tolerability profile of DA-1726, the company w","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mtva-positive-phase-1-mad-102700443.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2527425040","title":"BUZZ-U.S. STOCKS ON THE MOVE-Dow, Nike, Coty","url":"https://stock-news.laohu8.com/highlight/detail?id=2527425040","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527425040?lang=en_us&edition=fundamental","pubTime":"2025-04-16 01:53","pubTimestamp":1744739611,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Dow, Nike, CotyEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https://refini.tv/","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nL6N3QT0GU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DOW","AUR","COTY","NKE","CMPS","CVX","FLNC","LU1223082519.USD","NEM","ADM","LU0795875086.SGD","AMAT","PEP","FMC","LU2468319806.SGD","XOM","LU1280957306.USD","LU0788108826.HKD","SPNT","PNC","VLO","RDFN","CTVA","CHD","SKYE","CAT","IE00B5949003.HKD","ACI","HXL","IE00BBT3K403.USD","HWM","LU2249611893.SGD","BK4109","HUN","SEDG","JNJ","MP","EOSE","HPE","ALB","LVS","MTVA","HRL","CYTK","BK4108"],"gpt_icon":1},{"id":"2527412684","title":"Metavia Shares up 6.5% After Its Experimental Obesity Drug Shows Promise in Early-Stage Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2527412684","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527412684?lang=en_us&edition=fundamental","pubTime":"2025-04-15 21:31","pubTimestamp":1744723915,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nFWN3QT0ZB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2527971134","title":"BUZZ-MetaVia rises after experimental obesity drug shows promise in early-stage study","url":"https://stock-news.laohu8.com/highlight/detail?id=2527971134","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527971134?lang=en_us&edition=fundamental","pubTime":"2025-04-15 19:47","pubTimestamp":1744717676,"startTime":"0","endTime":"0","summary":"BUZZ-MetaVia rises after experimental obesity drug shows promise in early-stage study** Shares of drug developer MetaVia MTVA.O rise 17.9% to $2.17 premarket** Co says its experimental obesity drug showed a maximum reduction of 6.3% in body weight in a 28-day, 36-patient portion of an early-stage trial** The drug, DA-1726, on average reduced body weight by 4.3% ** Additionally, MTVA says DA-1726 showed waist circumference reduction of 1.6 inches on average, with a maximum reduction of 3.9 inches by day 33     ** \"We anticipate that greater weight loss may be seen in longer duration studies\" - co** In November, co changed its name to MetaVia from NeuroBo Pharmaceuticals** Up to last close, stock had fallen 9.4% YTD","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nL6N3QT0JV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"gpt_icon":0},{"id":"2527910184","title":"MetaVia announces ‘positive’ results from Part 2 of Phase 1 trial of DA-1726","url":"https://stock-news.laohu8.com/highlight/detail?id=2527910184","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527910184?lang=en_us&edition=fundamental","pubTime":"2025-04-15 19:05","pubTimestamp":1744715142,"startTime":"0","endTime":"0","summary":"MetaVia (MTVA) announced positive results from the 4-week multiple ascending dose Part 2 of its Phase 1 clinical trial of DA-1726, a novel, dual ox...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/metavia-announces-positive-results-from-part-2-of-phase-1-trial-of-da-1726?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/metavia-announces-positive-results-from-part-2-of-phase-1-trial-of-da-1726?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2527999814","title":"Metavia Inc: Additional Cohorts Being Added to Determine Maximum Tolerated Dose","url":"https://stock-news.laohu8.com/highlight/detail?id=2527999814","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527999814?lang=en_us&edition=fundamental","pubTime":"2025-04-15 19:01","pubTimestamp":1744714867,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nFWN3QT0KZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2527749998","title":"Metavia: With No Titration, Demonstrated Maximum Weight Loss of 6.3% and Mean Weight Loss of 4.3% at Day 26 at 32 Mg Dose","url":"https://stock-news.laohu8.com/highlight/detail?id=2527749998","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527749998?lang=en_us&edition=fundamental","pubTime":"2025-04-15 19:01","pubTimestamp":1744714867,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nFWN3QT0KZ:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2527499677","title":"Metavia Announces Positive Top-Line Data From the 4-Week Phase 1 Mad Trial of Da-1726, a Novel 3:1 Ratio Glp-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-in-Class Glucose Control (Glp-1R), Waist Reduction (Gcgr), and Tolerability","url":"https://stock-news.laohu8.com/highlight/detail?id=2527499677","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527499677?lang=en_us&edition=fundamental","pubTime":"2025-04-15 19:01","pubTimestamp":1744714867,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nFWN3QT0KZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2527499607","title":"Metavia Inc: Study Shows Strong Signal of Glucagon Efficacy at Day 33 at 32 Mg Dos","url":"https://stock-news.laohu8.com/highlight/detail?id=2527499607","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527499607?lang=en_us&edition=fundamental","pubTime":"2025-04-15 19:01","pubTimestamp":1744714867,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nFWN3QT0KZ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2527499153","title":"Metavia: Phase 1 Part 3 to Include Wegovy Early Drop-Out Patients to Explore Potential Superiority of Da-1726 on Safety and Tolerability","url":"https://stock-news.laohu8.com/highlight/detail?id=2527499153","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527499153?lang=en_us&edition=fundamental","pubTime":"2025-04-15 19:01","pubTimestamp":1744714867,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nFWN3QT0KZ:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2527492780","title":"MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and Tolerability","url":"https://stock-news.laohu8.com/highlight/detail?id=2527492780","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527492780?lang=en_us&edition=fundamental","pubTime":"2025-04-15 19:01","pubTimestamp":1744714860,"startTime":"0","endTime":"0","summary":"With No Titration, Demonstrated Compelling Maximum Weight Loss of 6.3% andMean Weight Loss of 4.3% at Day 26 at 32 mg Dose . Demonstrated Strong Signal of GLP-1R Efficacy with Maximum Lowering of Fasted Glucose of -18 mg/dLand Mean Lowering of -5.3 mg/dL at Day 26 at 32 mg Dose. Maximum Waist Circumference Reduction of3.9 Inches and Mean Reduction of 1.6 InchesDemonstrates Strong Signal ofGlucagon Efficacy at Day 33 at 32 mg Dose. Additional Cohorts Being Added to Determine Maximum Tolerated Dose. Planned Phase 1 Part 3 to Include Wegovy Early Drop-Out Patients to Explore Potential Superiority of DA-1726 on Safety and Tolerability, Along With Weight Loss and Other Secondary Endpoints. CAMBRIDGE, Mass., April 15, 2025 /PRNewswire/ -- MetaVia Inc. ,a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced positive results from the 4-week multiple ascending dose  Part 2 of its Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin  an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/metavia-announces-positive-top-line-110100485.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/metavia-announces-positive-top-line-110100485.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GLP","BK4202","BK4139","OXM","BK4023","LU1169589451.USD","LU1169590202.USD","BMI","MTVA","PK","BK4144","PD","BK4181","BK4157","BK4590","BK4218"],"gpt_icon":0},{"id":"2521073767","title":"U.S. RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Beacon Roofing, Liberty Energy","url":"https://stock-news.laohu8.com/highlight/detail?id=2521073767","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521073767?lang=en_us&edition=fundamental","pubTime":"2025-03-24 15:55","pubTimestamp":1742802941,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Beacon Roofing, Liberty EnergyMarch 24 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed compani","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nL3N3Q70IK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRM","IE00B0JY6N72.USD","ALNY","LU2264538146.SGD","BK4607","LU0642271901.SGD","LU2362540622.SGD","IE00BFTCPJ56.SGD","BRZE","LBRT","LU0738911758.USD","IE00B5949003.HKD","IE00B19Z3B42.SGD","LU0256863811.USD","LU2456880835.USD","RXST","SLB","FDX","LU1720051017.SGD","LU0251142724.SGD","HUBS","LEN","BBIO","LU0238689110.USD","LU0417517546.SGD","LU1201861249.SGD","NOV","IONS","IE00B4R5TH58.HKD","MTVA","LU2361045086.USD","DRI","LU0719512351.SGD","LU2458330243.SGD","LU1951200564.SGD","LU1804176565.USD","LU1366333091.USD","LU0557290698.USD","LU2236285917.USD","LU2756315318.SGD","VRTX","LU1064131342.USD","LU1429558221.USD","ALHC","LU0056508442.USD","LU1267930227.SGD","BECN","LU0792757196.USD","LU2362541513.USD"],"gpt_icon":1},{"id":"2521929661","title":"MetaVia Inc. Reports Progress in Cardiometabolic Drug Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2521929661","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521929661?lang=en_us&edition=fundamental","pubTime":"2025-03-22 11:53","pubTimestamp":1742615610,"startTime":"0","endTime":"0","summary":"Neurobo Pharmaceuticals, Inc. ( ($MTVA) ) has released its Q4 earnings. Here is a breakdown of the information Neurobo Pharmaceuticals, Inc. presen...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/metavia-inc-reports-progress-in-cardiometabolic-drug-development?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/metavia-inc-reports-progress-in-cardiometabolic-drug-development?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LU2065732104.USD","PRGS","BK4097","MTVA"],"gpt_icon":0},{"id":"2521815252","title":"MetaVia Price Target Maintained With a $12.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2521815252","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521815252?lang=en_us&edition=fundamental","pubTime":"2025-03-21 21:12","pubTimestamp":1742562720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MTVA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 21, 2025 09:12 ET (13:12 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA"],"gpt_icon":0},{"id":"2520945338","title":"MetaVia 2024 EPS $(3.56) Down From $(2.46) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2520945338","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520945338?lang=en_us&edition=fundamental","pubTime":"2025-03-20 19:50","pubTimestamp":1742471448,"startTime":"0","endTime":"0","summary":"MetaVia 2024 EPS $(3.56) Down From $(2.46) YoY","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44414209/metavia-2024-eps-3-56-down-from-2-46-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"MetaVia 2024 EPS $(3.56) Down From $(2.46) YoY","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA"],"gpt_icon":0},{"id":"2520458331","title":"Press Release: MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2520458331","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520458331?lang=en_us&edition=fundamental","pubTime":"2025-03-20 19:31","pubTimestamp":1742470260,"startTime":"0","endTime":"0","summary":"Top-Line Data From MAD Part 2 of the Phase 1 Trial of DA-1726 Expected in April of 2025. Announced Positive Top-Line 16-Week Results from the Phase 2a Trial of DA-1241 for the Treatment of MASH, in December, Demonstrating Direct Hepatic Action in Addition to Its Glucose Lowering Effect. $16.0 Million in Cash at End of Fourth Quarter Expected to Fund the Company Into the Third Quarter of 2025. CAMBRIDGE, Mass., March 20, 2025 /PRNewswire/ -- MetaVia Inc. , a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the year ended December 31, 2024 and provided a corporate strategic update.Mr. Kim continued, \"In December, we reported positive top-line 16-week results from the two-part Phase 2a clinical trial of DA-1241, a novel G-Protein-Coupled Receptor 119  agonist, in patients with presumed metabolic dysfunction-associated steatohepatitis . DA-1241 met the primary endpoint, achieving a reduction in alanine transaminase","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1878469433.USD","ALT","MTVA","BK4139","OXM","BK4202","GGT","BK4599"],"gpt_icon":0},{"id":"2503581014","title":"Zacks Small Cap Research 2024 Initiations and Best Ideas for 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2503581014","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503581014?lang=en_us&edition=fundamental","pubTime":"2025-01-13 17:00","pubTimestamp":1736758800,"startTime":"0","endTime":"0","summary":"Zacks Small Cap Research was hard at work in 2024 initiating analyst coverage on 40 companies. Each of our initiation reports provides a valuation, investment thesis and financial forecast model that comes from our 11 experienced analysts’ expertise and due diligence. Our work has generated investment ideas in health care, consumer electronics, finance technologies, transportation, AI-based products, and oil and gas production among other industries.The last year has been one fraught with risks, critical elections around the globe and multiple ongoing military conflicts among other material events. Despite this, index performance as measured by the S&P was positive in 2024, with large caps outperforming mid-caps and mid-caps surpassing small caps. Much of the strong performance was driven by tech stocks and the Magnificent Seven while other areas lagged.Ligand Pharmaceuticals  is a royalty aggregator which has a large opportunity set of biopharma names where it can deploy its capital f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zacks-small-cap-research-2024-090000334.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["USAW.SI","LU0566484027.USD","BK4152","BK4139","USJW.SI","TSYW.SI","MNQmain","TWI","BK4579","MTVA","VIOT",".IXIC","BK4191","LU1559883803.SGD","LGND","NQmain","TELO","NVIW.SI","CPSS","PSQ","QID","QLD","TQQQ","BK4166","BK4007","SQQQ"],"gpt_icon":1},{"id":"2502286335","title":"MetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2502286335","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502286335?lang=en_us&edition=fundamental","pubTime":"2025-01-10 21:05","pubTimestamp":1736514300,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Jan. 10, 2025 /PRNewswire/ --MetaVia Inc. ,a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it is holding an Advisory Committee meeting today, at the 9th Annual MASH-TAG 2025 Conference, to discuss the previously announced positive top-line 16-week results from the two-part Phase 2a clinical trial of DA-1241, a novel G-Protein-Coupled Receptor 119  agonist, in patients with presumed metabolic dysfunction-associated steatohepatitis . The MASH-TAG Conference is taking place January 9-11 at the Chateaux Deer Valley in Park City, Utah. Members of MetaVia's management and clinical team will be available in the Exhibit Hall at the Conference to discuss the results of the Phase 2a clinical trial of DA-1241.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/metavia-hold-advisory-committee-meeting-130500948.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/metavia-hold-advisory-committee-meeting-130500948.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","MTVA","BK4202","OXM"],"gpt_icon":0},{"id":"2495654684","title":"HC Wainwright Initiates MetaVia at Buy With $12 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2495654684","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495654684?lang=en_us&edition=fundamental","pubTime":"2024-12-30 20:21","pubTimestamp":1735561274,"startTime":"0","endTime":"0","summary":"HC Wainwright Initiates MetaVia at Buy With $12 Price Target","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MTVA"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":33,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MTVA\",params:#limit:5,,,undefined,":[{"date":"2025-03-20","symbol":"MTVA","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1742457600000,"name":null,"time":"Pre-Market","dateTimestamp":1742443200000,"actualEps":null},{"market":"US","date":"2024-11-07","symbol":"MTVA","fiscalQuarterEnding":"2024/09","expectedEps":-0.82,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"pre","actualEps":-0.55},{"market":"US","date":"2024-08-14","symbol":"MTVA","fiscalQuarterEnding":"2024/06","expectedEps":-1.38,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723608000000,"reportTimeType":"pre","actualEps":-1.85},{"market":"US","date":"2024-05-09","symbol":"MTVA","fiscalQuarterEnding":"2024/03","expectedEps":-0.95,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715227200000,"reportTimeType":"pre","actualEps":-1.32},{"date":"2024-03-28","symbol":"MTVA","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1711612800000,"name":null,"time":"Pre-Market","dateTimestamp":1711598400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MTVA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MTVA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":3,"updateTime":1735617600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MTVA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MTVA","date":"2025-04-17","current":-0.23033,"percent":1,"low":-0.807761,"twenty":-0.636267,"median":-0.537471,"eighty":-0.476844,"high":-0.23033,"avg":-0.55302,"sd":0.106731,"marketCap":6355270},"quantilePoints":[{"date":"2024-12-06","current":-0.714557,"twenty":-0.800304,"median":-0.792227,"eighty":-0.751814,"marketCap":19816823},{"date":"2024-12-13","current":-0.716111,"twenty":-0.79347,"median":-0.728538,"eighty":-0.7158,"marketCap":19859903},{"date":"2024-12-20","current":-0.546792,"twenty":-0.767348,"median":-0.716111,"eighty":-0.685354,"marketCap":15164177},{"date":"2024-12-27","current":-0.562326,"twenty":-0.746234,"median":-0.70213,"eighty":-0.556112,"marketCap":15594978},{"date":"2025-01-03","current":-0.655529,"twenty":-0.730091,"median":-0.686597,"eighty":-0.553006,"marketCap":18179781},{"date":"2025-01-10","current":-0.661742,"twenty":-0.733198,"median":-0.686597,"eighty":-0.564811,"marketCap":18352101},{"date":"2025-01-17","current":-0.58718,"twenty":-0.720771,"median":-0.663296,"eighty":-0.577238,"marketCap":16284258},{"date":"2025-01-24","current":-0.602714,"twenty":-0.720771,"median":-0.647762,"eighty":-0.584073,"marketCap":16715059},{"date":"2025-01-31","current":-0.584073,"twenty":-0.717664,"median":-0.630675,"eighty":-0.584073,"marketCap":16198098},{"date":"2025-02-07","current":-0.562326,"twenty":-0.716111,"median":-0.615141,"eighty":-0.562326,"marketCap":15594978},{"date":"2025-02-14","current":-0.512617,"twenty":-0.714557,"median":-0.608927,"eighty":-0.546792,"marketCap":14216416},{"date":"2025-02-21","current":-0.509511,"twenty":-0.704615,"median":-0.602714,"eighty":-0.540578,"marketCap":14130256},{"date":"2025-02-28","current":-0.453589,"twenty":-0.699297,"median":-0.58718,"eighty":-0.518583,"marketCap":12579374},{"date":"2025-03-07","current":-0.487763,"twenty":-0.688995,"median":-0.584073,"eighty":-0.503297,"marketCap":13527135},{"date":"2025-03-14","current":-0.467569,"twenty":-0.681626,"median":-0.568539,"eighty":-0.495468,"marketCap":12967095},{"date":"2025-03-21","current":-0.48401,"twenty":-0.667956,"median":-0.562326,"eighty":-0.487763,"marketCap":13354815},{"date":"2025-03-28","current":-0.48933,"twenty":-0.662363,"median":-0.546792,"eighty":-0.487763,"marketCap":13501595},{"date":"2025-04-04","current":-0.47992,"twenty":-0.656772,"median":-0.540578,"eighty":-0.485083,"marketCap":13241949},{"date":"2025-04-11","current":-0.429732,"twenty":-0.643102,"median":-0.539025,"eighty":-0.482756,"marketCap":11857170},{"date":"2025-04-17","current":-0.23033,"twenty":-0.636267,"median":-0.537471,"eighty":-0.476844,"marketCap":6355270}],"updateTime":1745002800269}}}